Dennis Cho Sells 806 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 806 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the transaction, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total value of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total value of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00.

Twist Bioscience Price Performance

TWST stock traded down $1.40 during trading on Friday, hitting $52.30. 883,044 shares of the stock traded hands, compared to its average volume of 786,851. The stock has a market cap of $3.12 billion, a price-to-earnings ratio of -15.47 and a beta of 1.87. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.54 and a debt-to-equity ratio of 0.03. The company has a 50 day simple moving average of $48.91 and a 200 day simple moving average of $46.13.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience's quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.75) earnings per share. Equities analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Institutional Trading of Twist Bioscience

Large investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience in the third quarter valued at about $34,000. Van ECK Associates Corp raised its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares during the last quarter. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. US Bancorp DE grew its stake in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the third quarter valued at approximately $95,000.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a report on Tuesday, February 4th. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research report on Thursday, October 17th. Wolfe Research initiated coverage on Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective on the stock. Finally, Robert W. Baird upped their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.